Regenerative Medical Technology Group Inc.

Regenerative Medical Technology Group Inc. reported a significant increase in revenue to $2.64 million for the first quarter of 2026, up from $1.36 million in the prior year. Despite higher gross profit, the company's net loss widened to $(876,274) from $(760,039) due to a substantial increase in interest expense. The company continues to face significant financial challenges, with an accumulated deficit of over $76 million and a working capital deficit of over $36 million, raising substantial doubt about its ability to continue as a going concern.

Regenerative Medical Technology Group Inc. (RMTG) faces substantial doubt about its ability to continue as a going concern, as highlighted by its independent registered public accounting firm due to a net loss and capital deficiency. The company also has $1,157,935 in matured unsecured promissory notes currently in default, with a risk of accelerating up to $16.6 million in secured debt if formal demand is made. Despite these financial challenges, RMTG outlined a strategic outlook for 2026, focusing on optimizing its vertically integrated regenerative medicine ecosystem, expanding its clinical network, and integrating AI-driven personalization. The strategy includes leveraging its ISSCA educational platform, Cellgenic manufacturing, and global market expansion across Latin America, the Middle East, and Southeast Asia.